News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
17,570 Results
Type
Article (493)
Company Profile (4)
Press Release (17073)
Section
Business (9191)
Career Advice (5)
Deals (1355)
Drug Development (1348)
FDA (185)
Job Trends (663)
News (11378)
Policy (713)
Tag
Academia (67)
Accelerated approval (1)
Allergies (4)
Alliances (479)
ALS (5)
Alzheimer's disease (26)
Antibody-drug conjugate (ADC) (12)
Approvals (205)
Artificial intelligence (4)
Autoimmune disease (6)
Bankruptcy (5)
Best Places to Work (690)
Biosimilars (1)
Biotechnology (5)
Bladder cancer (8)
Breast cancer (18)
Cancer (133)
Cardiovascular disease (6)
Career advice (5)
CAR-T (3)
Cell therapy (12)
Clinical research (1210)
Collaboration (13)
Compensation (7)
COVID-19 (133)
CRISPR (2)
C-suite (11)
Cystic fibrosis (3)
Data (184)
Depression (4)
Diabetes (9)
Diagnostics (206)
Drug discovery (1)
Duchenne muscular dystrophy (4)
Earnings (9195)
Events (1544)
Executive appointments (4)
FDA (344)
Frontotemporal dementia (2)
Funding (13)
Gene editing (3)
Gene therapy (8)
GLP-1 (23)
Government (158)
Guidances (109)
Healthcare (797)
IgA nephropathy (3)
Immunology and inflammation (4)
Immuno-oncology (2)
Indications (4)
Infectious disease (145)
Inflammatory bowel disease (4)
Influenza (8)
Intellectual property (2)
Interviews (1)
IPO (1195)
Job creations (18)
Job search strategy (4)
Labor market (1)
Layoffs (4)
Legal (67)
Liver cancer (2)
Lung cancer (15)
Lymphoma (19)
Manufacturing (9)
MASH (7)
Medical device (543)
Medtech (546)
Mergers & acquisitions (169)
Metabolic disorders (31)
mRNA (5)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuropsychiatric disorders (1)
Neuroscience (47)
NextGen: Class of 2026 (102)
Non-profit (131)
Obesity (12)
Opinion (1)
Ovarian cancer (6)
Pain (2)
Pancreatic cancer (1)
Parkinson's disease (4)
Patents (2)
Patient recruitment (8)
Peanut (4)
People (622)
Pharmaceutical (1)
Pharmacy benefit managers (1)
Phase 1 (292)
Phase 2 (445)
Phase 3 (611)
Pipeline (526)
Postmarket research (24)
Preclinical (97)
Press Release (1)
Prostate cancer (11)
Psychedelics (1)
Radiopharmaceuticals (6)
Rare diseases (14)
Real estate (46)
Regulatory (580)
Reports (2)
Research institute (42)
Rett syndrome (2)
RSV (4)
Schizophrenia (3)
Series A (2)
Sickle cell disease (1)
Special edition (1)
Spinal muscular atrophy (1)
Startups (15)
Vaccines (32)
Weight loss (9)
Women's health (2)
Date
Last 7 days (23)
Last 30 days (102)
Last 365 days (1045)
2026 (282)
2025 (1050)
2024 (1239)
2023 (1499)
2022 (1636)
2021 (1650)
2020 (4944)
2019 (1013)
2018 (688)
2017 (449)
2016 (258)
2015 (347)
2014 (231)
2013 (125)
2012 (175)
2011 (233)
2010 (238)
Location
Africa (7)
Arizona (9)
Asia (1071)
Australia (53)
California (390)
Canada (148)
China (24)
Colorado (21)
Connecticut (16)
Delaware (14)
Europe (1755)
Florida (61)
Georgia (10)
Illinois (39)
Indiana (44)
Japan (4)
Kansas (2)
Kentucky (1)
Louisiana (2)
Maine (5)
Maryland (44)
Massachusetts (334)
Michigan (13)
Minnesota (35)
Missouri (2)
Nevada (2)
New Hampshire (7)
New Jersey (133)
New York (86)
North Carolina (72)
Northern California (214)
Ohio (11)
Oregon (1)
Pennsylvania (94)
South America (24)
Southern California (148)
Tennessee (3)
Texas (103)
United States (1572)
Utah (15)
Virginia (1)
Washington D.C. (1)
Washington State (25)
Wisconsin (4)
17,570 Results for "209".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
·
8 min read
Press Releases
Nouscom to Present New Positive Phase 1b/2 Clinical and Translational Data on NOUS-209 Immunogenicity and Cancer Interception Potential in Lynch Syndrome Carriers at SITC 2025
October 31, 2025
·
7 min read
Press Releases
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer Interception in Lynch Syndrome Carriers
November 10, 2025
·
8 min read
Press Releases
Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 2025
October 13, 2025
·
8 min read
Press Releases
MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter
Investor Webcast: Thursday, August 28th at 4:00pm ET / 1:00pm PT
August 28, 2025
·
5 min read
Press Releases
Dialysis Market Size to Surpass USD 209.75 Billion by 2034
February 18, 2025
·
1 min read
Press Releases
Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers
April 29, 2025
·
8 min read
Press Releases
Failed Back Surgery Syndrome Market Size to Reach USD 20.9 Billion by 2035, Impelled by Rising Number of Spinal Surgeries
January 30, 2025
·
6 min read
Press Releases
Nouscom to Present Final Results from Successful Phase Ib/II Trial of NOUS-209 in People Living with Lynch Syndrome, Demonstrating Powerful Potential to Intercept Cancer in its Earliest Stages of Development
March 26, 2025
·
6 min read
Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome
Nouscom today announced that promising interim data from a Phase 1b trial evaluating NOUS-209 in Lynch Syndrome (LS) carriers was published in a Late-breaking Abstract and will be presented in an oral abstract presentation on 4th November 2023 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, USA.
October 31, 2023
·
5 min read
1 of 1,757
Next
